Nerviano Medical Sciences Receives Approval From the FDA to Enter Phase I Clinical Trials for Their Polo Like Kinase (PLK) Inhibitor

August 23rd, 2009 DOYLESTOWN, Pennsylvania - - Novel Self-Expanding Platform for Treatment of Coronary Artery Disease Receives European Regulatory Clearance Medical device pioneer, Prescient Medical, Inc., announced today that it has received European CE Mark (Conformite Europeene) approval to commercialize its vProtect(TM) Luminal Shield Stent System. The device is now approved for use in improving coronary artery luminal diameter in patients with symptomatic ischemic heart disease.

July 22nd, 2009 MUMBAI - - A Police Complaint has Been Lodged by Hospital Authorities Citing Fraudulent Activity by the Clinical Investigator Dr. A Bhattacharya Working at the GG Hospital and the MP Shah Medical College - Glenmark Not Only Acts as the Whistle-Blower but Also Discontinues its Clinical Study at the Mentioned Site After receiving approval from the Drug Controller General of India(DCGI) for a multi-centre Phase IIb clinical study for its lead COPD/asthma molecule, Oglemilast, Glenmark Pharmaceuticals Limited contracted Omnicare Clinical Research(Omnicare), a leading international CRO to conduct this Phase II asthma study on its behalf.

June 23rd, 2009 MUMBAI, India - Release Highlights - Melogliptin continues to demonstrate potential to be the best-in-class in achieving glycemic control with low incidence of hypoglycemia and neutral effect on body weight - Global Phase III trials likely to start by end 2009 - IND approved by USFDA - Glenmark takes a step closer towards becoming the first Indian company to have a truly global innovative drug for the world In the recently completed 12 week Phase IIb clinical trial in 494 patients with type 2 diabetes mellitus (T2DM), 'Melogliptin', Glenmark's investigational medicine from a new class of diabetes treatments called dipeptidyl peptidase 4 (DPP-4) inhibitors, improved glycemic control in patients with type 2 diabetes mellitus and exhibited excellent safety and tolerability profile. In addition, patients taking Melogliptin experienced low incidence of hypoglycemia and neutral effect on body weight.

June 8th, 2009 LONDON - New Clinical Data Presented at EHA Suggests That Omacetaxine May Provide a Useful Treatment Option for CML Patients Resistant to Multiple TKI Therapies ChemGenex Pharmaceuticals Limited (ASX:CXS) announced that positive, updated data from its phase 2/3 clinical trial study of omacetaxine in chronic myeloid leukemia (CML) patients with resistance to multiple tyrosine kinase inhibitors (TKIs) was presented at the 14th Congress of the European Hematology Association (EHA) in Berlin, Germany on Saturday. Dr. Meir Wetzler MD, Chief of the Division of the Leukemia, School of Medicine and Biomedical Sciences, University at Buffalo, Roswell Park Cancer Institute, a lead investigator in the study, presented the data.

May 5th, 2009 STOCKHOLM - Axelar AB today announced successful completion of the single-day oral dosing part of its ongoing phase I/II clinical trial on cancer patients with its new anti-cancer drug AXL1717,an insulin-like growth factor-1 (IGF-1) receptor inhibitor which has no effects on the closely related insulin receptor. The study is conducted in Sweden on patients having terminal cancer disease.

April 16th, 2009 LONDON - Chiltern International Limited (Chiltern), a global Clinical Research Organization (CRO) providing clinical development and staffing services in Europe, the Americas and India, today announced the acquisition of Vigiun, a full service Clinical Research Organization located in Sao Paulo, Brazil. Established in 1999 by Eduardo Forleo, MD, and Elisa Halker, BSN, Vigiun has extensive experience conducting clinical trials in a variety of therapeutic areas, in particular infectious disease, oncology, and respiratory.

April 5th, 2009 CALGARY, Canada - Orcrist Bio Inc. (ORC) a biotechnology company developing stem cell-mobilizing pharmaceuticals, announced today the approval of its Phase I, open-label, single-ascending-dose, safety study of HYC750 in healthy male volunteers, by the European Competent Authority in Seville, Spain.

March 26th, 2009 LONDON and TOKYO - Chiltern International Limited (Chiltern), a global Clinical Research Organization (CRO) that provides clinical development and staffing services in Europe, the Americas and India and its Asian partner EPS International Co. Ltd. (EPS INTERNATIONAL), a wholly owned subsidiary of EPS Co.

March 26th, 2009 MUNICH - Edoxaban (DU-176b) is a direct Factor Xa inhibitor and is developed to prevent thromboembolic events such as stroke and pulmonary embolism. The Phase II Edoxaban programme has been successfully completed for orthopaedic and cardiological indications.

March 23rd, 2009 SOUTHAMPTON, England - VA106483 Completes Phase IIa Trial and VA111913 Completes Phase I Dosing Vantia Therapeutics, a company focusing on first-in-class therapies for unmet medical needs, announces further clinical trial progress with its two lead development compounds, VA106483 for nocturia associated with benign prostatic hypertrophy (BPH) and VA111913 for dysmenorrhoea. The Phase IIa trial of VA106483 has completed, while dosing is complete in the Phase I trial of VA111913.

July 27th, 2009 NEW DELHI - The Ahmedabad-based Veeda Clinical Research organization is entering Malaysia's medical sector by setting up its advanced research unit at the Ampang Hospital in Kuala Lumpur by the year-end. India's fastest-growing clinical research organisation has selected the Ampang Hospital to conduct first phase clinical trials on humans under a quasi-commercial agreement with the Malaysian Health Ministry, The Star Online reports.

April 14th, 2009 HYDERABAD - GVK Biosciences (GVK BIO), Asia's leading integrated research services provider and Excel PharmaStudies (Excel), a leading Chinese Clinical Research Organization announced a strategic alliance to conduct clinical trials in Asia. The alliance provides clinical trial sponsors access to the scientific skills, talent pool, flexible resourcing, and cost-effectiveness of both India and China.

April 29th, 2009 WASHINGTON - An anti-cancer compound studied for treating blood cancers may also help in treating cancers of the head and neck, say researchers at Albert Einstein College of Medicine of Yeshiva University. The study involved a new class of chemotherapy agents known as histone deacetylase (HDAC) inhibitors, which affect the availability of genes that are transcribed and translated into proteins.

April 23rd, 2009 Correction: Dead polo horses storyWEST PALM BEACH, Fla. — In an April 22 story about 21 polo horses that died in Florida, The Associated Press reported erroneously that the Food and Drug Administration had refused to approve the French-made supplement Biodyl for use in the U.S.

February 4th, 2009 NEW DELHI - There is improvement in former prime minister Atal Bihari Vajpayee's clinical condition and his medical tests are normal, a hospital official said Thursday. Vajpayee, 85, was admitted to the VIP Intensive Care Unit (ICU) of the All India Institute of Medical Sciences (AIIMS) after he complained of difficulty in breathing Tuesday night.

August 19th, 2009 WASHINGTON - Officials of the University of California, San Diego Health Sciences and the Indian Institute of Technology (IIT) Kharagpur have signed a historic preliminary agreement to collaborate in the development of an International Medical Center (IMC) at IIT Kharagpur. This agreement - marked by a signing ceremony in Kharagpur, West Bengal, India - is the beginning of a strong educational, research and clinical partnership between UC San Diego Health Sciences and IIT, Kharagpur.

April 23rd, 2009 US Open Polo play resumes after Fla. horse deathsWELLINGTON, Fla.

May 6th, 2009 HYDERABAD - MakroCare, a global clinical services firm, provides clinical research support to pharmaceutical, biotechnology, and medical device industries, is taking a lead in the training of professionals for the clinical research industry by providing series of informational through workshop and seminars. Advanced GCP workshop will be held at CHITRAMAYEE Auditorium, State Arts Gallery, Kavuri Hills, Madhapur, Hyderabad on May 15.

April 21st, 2009 WASHINGTON - An official investigation has opened into the mysterious deaths of at least 21 horses in the US, the US Polo Association said Monday. The animals died just hours before a quarter-final match Sunday at the 105th US Open Polo Championship in Wellington, Florida.

July 21st, 2009 Contrave is an experimental weight-loss drug developed by Orexigen Therapeutics Inc. It has been shown to significantly aid weight loss in three late-stage clinical trials according to Associated Press reports.